Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>Products>This Product

1by1 with HTRF®

Product Description
1-by-1 with HTRF interaction assay is based on Homogeneous Time-Resolved Fluorescence, a highly sensitive and robust Time-Resolved FRET technique. This service allows you to test for direct binding in vitro.

Our offer includes :
- Scientific assistance from our protein-interaction experts
- Cloning
- Protein production and purification: both candidate proteins are produced in bacteria as fusions to different tags
- Protein labelling: each protein is labelled either directly or indirectly with anti-tag antibodies coupled to fluorescence donor and acceptor
- Competition test: to control that proteins are well recognized by the antibodies and to evaluate the optimal protein concentrations.
- HTRF interaction test
- Detailed report delivery with protocols, gel pictures, grpahics and comments

Our multi-tag approach and the use of the two donor-acceptor orientations for each protein pair allow for systematically investigating a large panel of combinations, thus increasing the chance of proper protein folding and fluorescence transfer.

Because the assay is homogeneous and requires only low nanomolar concentrations of proteins, multiple interactions can be evaluated simultaneously in a 384-well format.

This makes 1-by-1 with HTRF the perfect output to confirm ULTImate Y2H™ interactions in another system for publication! Our HTRF and Y2H plasmids are fully compatible for direct and efficient subcloning.

For more details, please go to:

HTRF® is a registered trademark of Cisbio International.

Product 1by1 with HTRF®
Company Hybrigenics Services SAS
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Hybrigenics Services SAS
3-5 Impasse Reille 75014 Paris France

Tel: +33 (0)1 58 10 38 29
Fax: +33 (0)1 58 10 38 48

Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.

Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos